INTEGRUM Stock Price, News & Analysis
Company Description
Integrum AB (IGRMF) is a medical technology company associated with the OPRA™ Implant System, a bone-anchored prosthetic solution for amputees. According to company communications, Integrum focuses on osseointegration-based implants that connect directly to the skeleton and are intended to support long-term outcomes for patients, clinicians, and healthcare partners.
The company is linked to the Nasdaq First North Growth Market under the symbol INTEG B and is described as the provider of the OPRA™ Implant System. Integrum highlights the role of its implant design and surgical technique in creating a stable interface at the skin and bone penetration site after healing.
OPRA™ Implant System and BondedMatrix™
Integrum has introduced the term BondedMatrix™ as part of a global marketing strategy for the OPRA™ Implant System. In its description, BondedMatrix™ refers to a biologically integrated barrier that connects the skin and bone at the penetration site after healing. This barrier is presented as a result of the OPRA™ system’s implant design and surgical method.
The company states that this characteristic has been part of OPRA™ for many years, and that the BondedMatrix™ designation is intended to provide a clearer way to communicate the system’s benefits. According to information shared by medical experts cited by Integrum, patients often seek a dependable and dry skin-implant interface, and BondedMatrix™ is described as a way to define this desired outcome.
Clinical Use and Osseointegration Focus
Integrum reports that the OPRA™ Implant System has been refined with global partners since the 1990s. The company states that more than 1,000 implants have been placed worldwide, supporting amputees in regaining mobility and independence. Its communications emphasize decades of experience with osseointegration and the clinical refinement of the associated surgical technique.
Medical professionals referenced in Integrum’s materials describe the OPRA™ Implant System as a bone-anchored prosthetic option and discuss clinical experience with patient outcomes and the BondedMatrix™ concept. These references underscore the company’s focus on long-term integration of the implant with both bone and surrounding soft tissue.
Engagement with Clinicians and Prosthetists
Integrum’s marketing and educational activities include participation in professional meetings such as the American Orthotic & Prosthetic Association’s National Assembly. At such events, the company presents its global marketing strategy, hosts educational sessions, and provides information aimed at clinicians, prosthetists, and patients about the OPRA™ Implant System and BondedMatrix™.
The company describes its BondedMatrix™ initiative as a way to create a common language that makes the advantages of OPRA™ more accessible to healthcare professionals and patients. By naming and defining the skin-bone interface outcome, Integrum aims to support clearer communication around expectations and clinical results.
Positioning and Target Audience
Based on available information, Integrum positions itself around bone-anchored prosthetics and osseointegration, with a focus on amputees who may benefit from a direct skeletal attachment for their prosthetic limb. Its messaging is directed at medical specialists, prosthetists, and healthcare partners involved in advanced amputation care, as well as patients considering or using bone-anchored prosthetic solutions.
The company’s communications emphasize the combination of implant design, surgical technique, and long-term clinical experience as central elements of the OPRA™ Implant System. The BondedMatrix™ terminology is presented as a way to encapsulate these elements into a single, patient- and clinician-facing concept.
Key Concepts
- OPRA™ Implant System: Described by Integrum as a bone-anchored prosthetic implant system for amputees.
- BondedMatrix™: A coined term used by Integrum for the biologically integrated barrier at the skin and bone penetration site after healing, associated with OPRA™.
- Osseointegration: The underlying principle referenced in Integrum’s materials, relating to the integration of the implant with bone and soft tissue.
- Clinical Experience: Integrum cites decades of refinement of the OPRA™ surgical technique with global partners and more than 1,000 implants placed worldwide.
Stock Performance
SEC Filings
No SEC filings available for INTEGRUM.
Financial Highlights
Upcoming Events
Short Interest History
Short interest in INTEGRUM (IGRMF) currently stands at 7.1 thousand shares, up 1000.0% from the previous reporting period, representing 0.1% of the float. Over the past 12 months, short interest has increased by 58725%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for INTEGRUM (IGRMF) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 16566.5% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 6.0 to 1000.0 days.